- Worldwide Sales Growth of 13.8 Percent -
- Worldwide Pharmaceutical Sales Increased 14.3 Percent -
- Worldwide Medical Products Sales Increased 13.7 Percent -
- Five New Product Approvals in the First Quarter -
ABBOTT PARK, Ill., April 16 /PRNewswire-FirstCall/ -- Abbott (NYSE:
ABT) today announced financial results for the first quarter ended March
* Diluted earnings per share, excluding specified items, were
$0.63, reflecting 14.5 percent growth, at the upper end of Abbott's
previously announced guidance range of $0.61 to $0.63. Diluted
earnings per share under Generally Accepted Accounting Principles
(GAAP) were $0.60, up 33.3 percent.
* Worldwide sales in the first quarter increased 13.8 percent to
$6.8 billion, including a favorable 5.5 percent effect of exchange
* Worldwide pharmaceutical sales increased 14.3 percent driven by
double-digit growth in HUMIRA(R), Niaspan(R) and Kaletra(R) and
9.8 percent growth in TriCor(R). Abbott forecasts global HUMIRA
sales of more than $4 billion in 2008.
* Worldwide medical products sales increased 13.7 percent, driven by
14.3 percent growth in worldwide Diabetes Care sales, 22.0 percent
growth in international diagnostics sales, and 34.7 percent growth
in international Vascular sales.
* Worldwide nutritional products sales were led by 20.8 percent growth
in international nutritionals, with continued strong performance in
key emerging growth markets.
* In March, Abbott and Takeda announced an agreement to conclude the
TAP joint venture, evenly splitting the assets. Abbott will receive
full U.S. ownership of Lupron, a complementary product to Abbott's
emerging oncology pipeline,hare, for acquisition
integration; partially offset by an after-tax gain of $9 million, or
$0.01 per share, on sales of Boston Scientific stock.
2007 Net Earnings Excluding Specified Items excludes after-tax charges
of $57 million, or $0.04 per share, for acquisition integration,
$75 million, or $0.05 per share, related to fair value adjustments of
Abbott's investment in Boston Scientific stock and related gain-sharing
aspect, and $55 million, or $0.03 per share, for cost reduction
initiatives and other, partially offset by $31 million, or $0.02 per
share, for suspended depreciation and amortization related to the
proposed sale of the diagnostics business.
NOTE: See attached questions and answers section for further explanation
of Consolidated Statement of Earnings line items.
n/m = Percent change is not meaningful.
Questions & Answers
Q1) What drove the 14.3 percent worldwide pharmaceutical sales growth?
A1) International pharmaceutical sales increased 25.1 percent during the
quarter, including an 11.9 percent favorable impact from exchange.
International growth was driven by HUMIRA, which grew nearly
70 percent, and Kaletra, which grew 31.2 percent, based on the
continued strength of the international launch of Kaletra tablets.
U.S. pharmaceutical sales growth of 3.6 percent was impacted by the
expected decline in Omnicef sales, as generic competition for the
product began in May 2007. Excluding the impact from Omnicef, U.S.
pharmaceutical sales increased approximately 14 percent. Growth in
the quarter was driven by HUMIRA, which increased nearly 40 percent
as market demand continued to grow across the rheumatology,
dermatology and gastroenterology segments. The launch of the
psoriasis indication is proceeding well, with strong HUMIRA market
share gains in the first two months since launch. Abbott forecasts
global HUMIRA sales of more than $4 billion in 2008. Niaspan and
TriCor also performed well, increasing 24.2 percent and 9.8 percent,
respectively. Total lipid franchise sales growth, including TriCor,
Niaspan and Simcor, exceeded 20 percent.
Q2) What drove the double-digit growth in global nutritionals and
medical products sales?
A2) Global Nutritional sales performance was led by 20.8 percent growth
in international nutritionals, including a 6.9 percent favorable
impact from exchange, with continued strong growth in Latin American
and Asian markets.
Medical products sales growth of 13.7 percent was led by global
diagnostics sales, which increased 17.1 percent, including an
8.1 percent favorable impact from exchange. Point of care sales grew
21.7 percent and Abbott Molecular also increased more than
21 percent. Worldwide Diabetes Care sales grew 14.3 percent. Abbott
Vascular achieved sales of more than $450 million, led
by 34.7 percent international growth. Results include continued
growth in Coronary Stents, including Xience V internationally. Other
Coronary sales reflect lower third-party catheter sales due to an
expected year-over-year decline in the percutaneous coronary
intervention (PCI) market. However, U.S. PCI volumes were up
sequentially versus the fourth quarter of 2007, and U.S.
drug-eluting stent (DES) penetration improved to the mid-to-high
60 percent range in March. In addition, in the first quarter, Abbott
launched Xience V in France, Europe's second- largest DES market,
and the launch is off to a strong start.
Q3) What drove SG&A and R&D spending in the quarter?
A3) The company is on track for a significant number of major new
product launches in 2008. In the quarter, Abbott received approval
for five new products or indications, including HUMIRA to treat
psoriasis and juvenile rheumatoid arthritis, Simcor to treat
cholesterol, and the FreeStyle Freedom Lite and the FreeStyle
Navigator glucose monitoring systems.
SG&A expense included new and ongoing promotional initiatives,
including spending to support the launch of two new indications for
HUMIRA, the launch of Simcor and the upcoming U.S. launch of Xience
V, which the company expects in the second quarter of 2008.
R&D expense in the quarter was 9.2 percent of sales, in line with
previous guidance. The comparison to the prior year is impacted by
the timing of R&D spending, with higher levels of R&D expense in the
prior year supporting significant late-stage pipeline activity.
Growth in R&D spending for the full year is expected to be in the
mid-to-high single digits.
Q4) How does the first-quarter gross margin profile compare to the prior
A4) The gross margin ratio before and after specified items is shown
below (dollars in millions):
Cost of Gross Cost of Gross
Products Gross Margin Products Gross Margin
Sold Margin % Sold Margin %
As reported $2,961 $3,805 56.2% $2,592 $3,354 56.4%
Adjusted for specified items:
Cost reduction initiatives
and other ($31) $31 0.5% ($56) $56 0.9%
Acquisition integration ($4) $4 0.1% ($23) $23 0.4%
Suspended depreciation and
amortization - - - $32 ($32) (0.5%)
As adjusted $2,926 $3,840 56.8% $2,545 $3,401 57.2%
The first-quarter 2008 adjusted gross margin ratio was 56.8 percent.
The comparison to 2007 was negatively impacted by generic
competition for Omnicef and the impact of foreign exchange on the
ratio. The gross margin ratio for the full year is expected to be
approximately 58 percent.
Q5) How did specified items affect reported results?
A5) Specified items impacted first-quarter results as follows (dollars
in millions, except earnings-per-share data):
Pre-tax tax EPS Pre-tax tax EPS
As reported $1,161 $938 $0.60 $841 $698 $0.45
Adjusted for specified items:
Cost reduction initiatives
and other $44 $37 $0.02 $70 $55 $0.03
Acquired in-process R&D $19 $15 $0.01 - - -
Acquisition integration $9 $7 $0.01 $71 $57 $0.04
(Gain) on sale of BSX stock
and fair-value adjustments
for BSX stock and financial
instruments ($11) ($9) ($0.01) $124 $75 $0.05
Suspended depreciation and
amortization - - - ($39) ($31) ($0.02)
As adjusted $1,222 $988 $0.63 $1,067 $854 $0.55
Cost reduction initiatives and other relate primarily to remaining
costs associated with previously announced efforts to improve
efficiencies in our global manufacturing operations. This includes
actions announced last year to streamline operations in our vascular
business. Acquired in-process research and development
relates to a molecular diagnostic technology investment that took
place in the quarter. Acquisition integration primarily relates to
remaining costs associated with acquisitions. Regarding Boston
Scientific (BSX) stock, the amount in the first quarter of 2008
relates to realized gains on the disposition of BSX stock and in the
prior year relates primarily to changes in fair value. Amounts this
quarter represent final gains on sale as all shares of BSX stock
have now been sold.
The pre-tax impact of the specified items by Consolidated Statement
of Earnings line item is as follows (dollars in millions):
Cost of Other
Sold R&D IPR&D SG&A Expense
As reported $2,961 $620 $19 $2,018 ($10)
Adjusted for specified items:
Cost reduction initiatives and other $31 - - $13 -
Acquired in-process R&D - - $19 - -
Acquisition integration $4 $1 - $4 -
(Gains) on sales of BSX stock - - - - ($11)
As adjusted $2,926 $619 - $2,001 $1
Q6) What was the tax rate in the quarter?
A6) In line with the previous forecast, the tax rate this quarter was
Q7) How did the TAP joint venture perform this quarter?
A7) Income from the TAP joint venture was in line with previous
forecasts. Prevacid sales were $550 million and Lupron sales were
In March, Abbott and Takeda announced an agreement to conclude the
TAP joint venture, evenly splitting the assets. Abbott expects the
transaction to be neutral to 2008 earnings per share and neutral or
better over the next five years. The transaction is expected to
close in the second quarter of 2008.
After the close of the transaction, Abbott will no longer record TAP
joint venture income. Instead, U.S. Lupron sales and costs
associated with the franchise will be included in Abbott's operating
results. Abbott will also record, as other income, the estimated
future cash payments from Takeda of approximately $1.5 billion over
the next five years based on TAP's current and future product
Q8) What are some near-term opportunities from Abbott's pipeline?
A8) Abbott has a number of promising late-stage programs in its
pharmaceutical and medical products pipeline, including:
o Psoriasis -- Launched in Europe and the United States in
the first quarter of 2008.
o Juvenile RA -- Received regulatory approval in the first
quarter of 2008.
o Ulcerative colitis -- Currently in Phase III development.
o RA in Japan -- Received approval in April 2008.
* XIENCE V Drug-Eluting Stent (DES) -- Launched outside the
United States, submitted to the U.S. Food and Drug
Administration (FDA) and is currently under regulatory review.
In the fourth-quarter 2007, an FDA advisory panel recommended
approval of Xience V. Abbott expects a U.S. launch in the
second-quarter 2008. Two-year results from the U.S. pivotal
trial, SPIRIT III, have been accepted as a LateBreaker
presentation at the EuroPCR meeting in mid-May.
* Controlled-release Vicodin -- A controlled-release form of
Abbott's pain brand, Vicodin, was submitted for U.S. regulatory
approval in the fourth quarter of 2007. Results from the
pivotal Phase III clinical trial will be presented at the
American Pain Society meeting in May.
* Simcor -- Simcor, a combination therapy to address both HDL and
LDL cholesterol, was approved in the United States in the first
quarter of 2008.
* TriLipix (ABT-335) -- TriLipix, a next-generation fenofibrate,
was submitted for U.S. regulatory approval in the fourth
quarter of 2007. Phase III data were presented at the American
College of Cardiology meeting in March. In addition, TriLipix
is part of the fixed-dose combination with Crestor that is in
Phase III development.
* ABT-874 -- In Immunology, Abbott's anti-IL-12/23 biologic,
ABT-874, has demonstrated promising results in early studies
for Crohn's disease and psoriasis. Abbott moved ABT-874 into
Phase III development for psoriasis in December 2007.
* Flutiform -- A combination asthma treatment in Phase III
development, Flutiform is expected to launch in 2009.
* Diabetes Care Pipeline -- FreeStyle Freedom Lite was launched
internationally last year and was recently launched in the
United States. Abbott's FreeStyle Navigator Continuous Glucose
Monitoring System was launched in Europe last year and was
approved in the United States in the first quarter of 2008.
Also in development is a fully integrated blood glucose
monitoring system combining a meter, test strips and lancing
capabilities in one device.
* m2000 Molecular Diagnostics System -- Last year, Abbott
received FDA approval for the RealTime HIV-1 viral load test
for use on the m2000 molecular diagnostics system. Abbott
expects to expand its U.S. menu of infectious disease assays
over the next few years.
* Core Laboratory Diagnostics -- In April, Abbott introduced the
ARCHITECT i1000SR immunochemistry analyzer in the United
States, expanding its ARCHITECT family of diagnostic instrument
systems for clinical laboratories.
Q9) What are some mid- and early-stage opportunities in Abbott's
A9) Abbott is advancing leading-edge scientific discoveries in its
mid- and early-stage pharmaceutical and medical products pipeline.
Following are selected areas of emphasis:
o Abbott's neuroscience pipeline includes several unique
approaches for treating a number of diseases including
schizophrenia, ADHD, Alzheimer's disease and pain.
Compounds under development target neuronal nicotinic
receptors (NNRs), which play a role in regulating pain,
memory and other neurological functions.
o In 2007, Abbott announced a collaboration with Genentech
to develop and commercialize two Abbott-discovered
oncology compounds. These include a multi-targeted kinase
inhibitor and Bcl-2 family protein antagonist. Both
represent promising, unique approaches to treating cancer.
Abbott and Genentech will work together on all aspects of
research, development and commercialization.
o Additional oncology compounds in Abbott's pipeline that
are not part of the collaboration include: a
PARP-inhibitor, which prevents DNA repair in cancer cells,
enhancing the effectiveness of current cancer therapies;
an oral anti-mitotic in Phase II for non-small cell lung
cancer and neuroblastoma; and, a biologic anti-tumor agent
with a novel mechanism of action.
* Hepatitis C
o Abbott has partnered with Enanta Pharmaceuticals to
develop protease inhibitors for the treatment of hepatitis
C (HCV), which affects more than 170 million people
worldwide. Abbott also has an internal HCV polymerase
program in early-stage development.
* Bioabsorbable Drug-Eluting Stent
o Abbott has presented promising data from the world's first
clinical trial (ABSORB) for a fully-bioabsorbable
drug-eluting stent (DES) to treat coronary artery disease.
The bioabsorbable DES is designed to be slowly and
completely metabolized by the body over time.as well as future cash payments over the
next five years.
* In the quarter, Abbott received five key regulatory approvals:
HUMIRA for psoriasis and for juvenile rheumatoid arthritis,
Simcor(R) for cholesterol, and the FreeStyle Freedom Lite(TM) and
FreeStyle Navigator(R) glucose monitoring systems.
"Abbott started 2008 with a strong first quarter, following
double-digit sales and earnings growth last year," said Miles D. White,
chairman and chief executive officer, Abbott. "In addition, we received
five key new product approvals during the quarter. The continued
productivity of our late-stage pipeline, combined with the underlying
strength of our broad mix of businesses, gives us a high level of
confidence in our future growth outlook."
The following is a summary of first-quarter 2008 sales.
Sales Summary - Impact of
Quarter Ended 3/31/08 1Q08 % Change Exchange on
($ millions) vs. 1Q07 % Change
Total Sales $6,766 13.8 5.5
Total U.S. Sales $3,043 3.7 (a) ---
Total International Sales $3,723 23.6 10.9
Worldwide Pharmaceutical Sales $3,854 14.3 (a) 5.9
U.S. Pharmaceuticals $1,752 3.6 (a) ---
International Pharmaceuticals $2,102 25.1 11.9
Worldwide Nutritional Sales $1,110 10.8 3.0
U.S. Nutritionals $583 3.0 ---
International Nutritionals $527 20.8 6.9
Worldwide Diagnostics Sales (b) $832 17.1 8.1
U.S. Diagnostics $211 4.6 ---
International Diagnostics $621 22.0 11.3
Worldwide Vascular Sales $452 7.6 4.9
U.S. Vascular $214 (12.0) ---
International Vascular $238 34.7 11.7
Other Sales (c) $518 17.3 4.7
(a) Reflects the impact of generic competition for Omnicef in May 2007.
(b) Includes sales from the molecular diagnostics and core laboratory
diagnostics businesses, which includes point of care.
(c) Includes sales from diabetes, bulk pharmaceuticals, spine and animal
Note: See "Consolidated Statement of Earnings" for more information.
The following is a summary of Abbott's first-quarter 2008 sales for selected products.
Quarter Ended 3/31/08
Percent Percent Percent
(dollars in millions) Change Rest Change Change
U.S. vs. of vs. Global vs.
Sales 1Q07 World 1Q07 Sales 1Q07
HUMIRA $402 38.8 $476 68.9 (a) $878 53.7
Depakote $341 11.7 $24 12.2 $365 11.7
Kaletra $113 (3.2) $240 31.2 (b) $353 17.8
TriCor $245 9.8 --- --- $245 9.8
Biaxin (clarithromycin) $6 (17.4) $216 (0.4)(c) $222 (1.0)
Ultane/Sevorane $44 (9.0) $143 13.8 (d) $187 7.4
Niaspan $176 24.2 --- --- $176 24.2
Synthroid $94 (16.5) $21 28.1 $115 (10.7)
Pediatric Nutritionals $305 4.5 $293 24.5 $598 13.5
Adult Nutritionals $271 3.9 $234 16.4 (e) $505 9.3
Abbott Diabetes Care $136 3.8 $189 23.2 (f) $325 14.3
Coronary Stents $75 (11.8) $114 52.5 (g) $189 18.2
Other Coronary $78 (12.3) $87 19.8 (h) $165 2.0
Endovascular $61 (11.8) $37 25.8 (i) $98 (0.6)
(a) Without the positive impact of exchange of 17.3 percent, HUMIRA sales
increased 51.6 percent internationally.
(b) Without the positive impact of exchange of 10.5 percent, Kaletra sales
increased 20.7 percent internationally.
(c) Without the positive impact of exchange of 9.6 percent, clarithromycin
sales decreased 10.0 percent internationally.
(d) Without the positive impact of exchange of 9.4 percent, Sevorane sales
increased 4.4 percent internationally.
(e) Without the positive impact of exchange of 8.9 percent, Adult
Nutritionals sales increased 7.5 percent internationally.
(f) Without the positive impact of exchange of 12.3 percent, Abbott
Diabetes Care sales increased 10.9 percent internationally.
(g) Without the positive impact of exchange of 13.2 percent, Coronary
Stents sales increased 39.3 percent internationally.
(h) Without the positive impact of exchange of 9.7 percent, Other Coronary
sales increased 10.1 percent internationally.
(i) Without the positive impact of exchange of 12.4 percent, Endovascular
sales increased 13.4 percent internationally.
* Simcor(R) Approved in United States -- Abbott received U.S. Food and
Drug Administration (FDA) approval of its cholesterol therapy,
Simcor, a fixed-dose combination of Niaspan(R) and simvastatin.
Simcor combines these two well-established medications to target LDL
(bad cholesterol), HDL (good cholesterol) and triglycerides in a
* HUMIRA(R) Indications Approved
o Psoriasis -- Abbott received FDA approval for HUMIRA to treat
moderate to severe plaque psoriasis. In clinical trials, nearly
75 percent of patients treated with HUMIRA achieved a
75 percent reduction in psoriasis symptoms. Psoriasis affects
125 million people worldwide.
o Juvenile Rheumatoid Arthritis (JRA) -- Also in the quarter,
Abbott received FDA approval for HUMIRA to treat moderate to
severely active polyarticular juvenile idiopathic arthritis,
commonly referred to as JRA in the United States.
o RA in Japan -- In April, Abbott also received Japanese approval
for HUMIRA to treat RA.
* TAP Joint Venture to Conclude -- In March, Abbott and Takeda
Pharmaceutical announced an agreement to conclude their 31-year TAP
joint venture. Abbott and Takeda will evenly split the value and
assets of the joint venture, with Abbott receiving full ownership of
the oncology treatment, Lupron, including its U.S. commercial
organization, as well as future cash payments from Takeda over the
next five years. The transaction is expected to close in the second
quarter of 2008.
* Data Presented at the American College of Cardiology (ACC)
o TriLipix(R) -- Abbott presented Phase III data on TriLipix,
formerly known as ABT-335, Abbott's next-generation fenofibrate
therapy. Data demonstrated that TriLipix, in combination with
statin therapy, is safe and effective at improving three key
lipids, HDL, LDL and triglycerides.
o Xience(TM) V -- Abbott also presented data on its Xience V
drug-eluting stent. Results from the SPIRIT II clinical trial
outside the United States demonstrated that after two years,
patients with the Xience V stent experienced a 40 percent
reduction in major adverse cardiac events (MACE) compared to
Boston Scientific's Taxus drug-eluting stent. Two-year results
from Abbott's U.S. pivotal trial, SPIRIT III, have been
accepted as a LateBreaker presentation at the upcoming EuroPCR
meeting in mid-May.
* FreeStyle Navigator(R) and FreeStyle Freedom Lite(TM) Available in
United States -- In March, Abbott received FDA approval of the
FreeStyle Navigator Continuous Glucose Monitoring System. Worn on
the abdomen or arm, FreeStyle Navigator monitors glucose levels and
provides minute-by-minute trend information. The FreeStyle Freedom
Lite blood glucose monitor is also now available, improving patient
convenience by eliminating the manual calibration required by most
* ARCHITECT(R) i1000SR(R) Approved -- Abbott introduced the ARCHITECT
i1000SR immunochemistry analyzer in the United States, expanding its
ARCHITECT family of diagnostic instrument systems. Designed to help
improve productivity in small-volume labs, the instrument addresses
common laboratory workflow challenges through innovative sample
processing and reagent management.
* Abbott Molecular Development Agreement -- Abbott entered into an
agreement with Genentech, Hoffmann-La Roche and OSI Pharmaceuticals
to develop a gene-based test to assess the clinical benefit of
Tarceva (erlotinib). Under the agreement, Abbott will develop a test
to detect extra copies of the epidermal growth factor receptor
(EGFR) gene in non-small cell lung cancer patients.
Abbott confirms earnings-per-share guidance for the full-year 2008 and issues earnings-per-share guidance for the second-quarter 2008
Abbott is confirming earnings-per-share guidance for the full-year 2008 of $3.20 to $3.25, and is providing earnings-per-share guidance of $0.78 to $0.80 for the second quarter, both excluding specified items. As previously announced, Abbott expects the TAP transaction to close in the second quarter and to be neutral to earnings per share in 2008 and neutral or better over the next five years.
Abbott forecasts specified items for the full-year 2008 of approximately $0.08 per share, including previously announced cost reduction initiatives. Including specified items, projected earnings per share under GAAP would be $3.12 to $3.17.
Abbott forecasts specified items for the second-quarter 2008 of approximately $0.03 per share, primarily associated with previously announced cost reduction initiatives. Including these specified items, projected earnings per share under GAAP would be $0.75 to $0.77.
Abbott increases quarterly dividend
On Feb. 15, 2008, the board of directors increased the company's quarterly common dividend to 36 cents per share, an increase of 10.8 percent. The cash dividend is payable May 15, 2008, to shareholders of record at the close of business on April 15, 2008. This marks the 36th consecutive year that Abbott has increased its dividend payout and the 337th consecutive dividend paid by Abbott.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the
company's Web site at http://www.abbott.com. Abbott will webcast its live
first-quarter earnings conference call through its Investor Relations Web
site at http://www.abbottinvestor.com at 8 a.m. Central time today. An
archived edition of the call will be available after 11 a.m. Central time.
- Private Securities Litigation Reform Act of 1995 -
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements
for the purposes of the Private Securities Litigation Reform Act of 1995.
We caution that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated. Economic, competitive, governmental, technological and other
factors that may affect Abbott's operations are discussed in Item 1A, "Risk
Factors," to our Annual Report on Securities and Exchange Commission Form
10-K for the year ended Dec. 31, 2007, and are incorporated by reference.
We undertake no obligation to release publicly any revisions to
forward-looking statements as a result of subsequent events or
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
First Quarter Ended March 31, 2008 and 2007
2008 2007 Change
Net Sales $6,765,603,000 $5,945,561,000 13.8
Cost of products sold 2,961,072,000 2,592,011,000 14.2
Research and development 619,957,000 619,056,000 0.1
Acquired in-process research &
development 18,700,000 --- n/m
Selling, general and
administrative 2,018,033,000 1,786,869,000 12.9
Total Operating Cost and
Expenses 5,617,762,000 4,997,936,000 12.4
Operating earnings 1,147,841,000 947,625,000 21.1
Net interest expense 93,178,000 124,205,000 (25.0)
Net foreign exchange (gain) loss 6,221,000 4,851,000 28.2
(Income) from TAP Pharmaceutical
Products Inc. joint venture (101,942,000) (146,632,000) (30.5)
Other (income) expense, net (10,342,000) 124,536,000 n/m 1)
Earnings before taxes 1,160,726,000 840,665,000 38.1
Taxes on earnings 222,859,000 143,128,000 55.7
Net Earnings $937,867,000 $697,537,000 34.5
Net Earnings Excluding Specified
Items, as described below $987,724,000 $854,107,000 15.6 2)
Diluted Earnings Per Common
Share $0.60 $0.45 33.3
Diluted Earnings Per Common
Share, Excluding Specified
Items, as described below $0.63 $0.55 14.5 2)
Average Number of Common Shares
Outstanding Plus Dilutive Common
Stock Options and Awards 1,560,567,000 1,558,234,000
1) Other (income) expense, net in 2008 and 2007 is primarily related to
Abbott's ownership of Boston Scientific stock. These items have been
reflected as specified items as discussed in Q&A Answer 5.
2) 2008 Net Earnings Excluding Specified Items excludes after-tax charges
of $37 million, or $0.02 per share, for cost reduction initiatives and
other, $15 million, or $0.01 per share, for acquired in-process
research & development related to a molecular diagnostic technology
investment and $7 million, or $0.01 per s
Copyright©2008 PR Newswire.
All rights reserved